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Background: Xenotropic murine leukemia virus-related virus (XMRV) is a gammaretrovirus reported to be
associated with prostate cancer (PC) and chronic fatigue syndrome (CFS). While the association of XMRV with CFS
and PC has recently been discredited, no studies have been performed in Australian patients to investigate the
association between PC and XMRV or related murine leukemia virus (MLV) in matched PC and normal tissue.
Methods: Genomic DNA (gDNA) was purified from matched normal and cancer formalin-fixed paraffin-embedded
(FFPE) prostate tissue from 35 Australian PC patients with Gleason scores ranging from 7 – 10. The presence of the
ribonuclease L (RNase L) polymorphism R462Q was determined by allele specific PCR. Samples were screened for
XMRV and related murine leukemia virus (MLV) variants by qPCR. Contaminating mouse DNA was detected using
qPCR targeting mouse intracisternal A particle long terminal repeat DNA.
Results: gDNA was successfully purified from 94% (66/70) of normal and cancer FFPE prostate tissues. RNase L
typing revealed 8% were homozygous (QQ), 60% were heterozygous (RQ) and 32% were wild-type (RR) for the
RNase L mutation. None of the 66 samples tested were positive for XMRV or related MLV sequences using broad
MLV or XMRV specific primers with detection sensitivities of 1 viral copy of MLV/XMRV and XMRV DNA, respectively.
Conclusions: Using highly sensitive qPCR we found no evidence of XMRV or related gammaretroviruses in prostate
tissues from 35 Australian PC patients. Our findings are consistent with other studies demonstrating that XMRV is a
laboratory contaminant that has no role in the aetiology of PC.Introduction
Prostate cancer (PC) is one of the most commonly diag-
nosed cancers in men resulting in approximately 3,300
deaths in Australia per year. While the aetiology of PC
remains poorly understood, infection and associated in-
flammation are risk factors in PC development [1]. The
rationale for a recent search for a viral origin for PC was
based on the observation that a reduced activity variant
of the antiviral RNASEL gene (R462Q) was associated
with familial PC [2]. A gammaretrovirus named xenotro-
pic murine leukemia virus-related virus (XMRV) was
identified in cDNA samples from seven of 11 R462Q* Correspondence: john.pedersen@tissupath.com.au
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reproduction in any medium, provided the orhomozygous (QQ) cases using a novel DNA microarray
(Virochip) containing oligonucleotides comprising con-
served sequences from known viral genomes [2]. How-
ever, the association of XMRV with the QQ RNASEL
variant was observed in some [3] but not all studies
[4,5]. XMRV was reportedly linked with higher-grade PC
cancers suggesting that its presence may be a useful bio-
marker for severe disease [4]. However, there was dis-
cordance with regard to the cellular location of XMRV
in the prostate where positive signals by fluorescence
in situ hybridization (FISH) and immunohistochemistry
assays were observed in either malignant epithelium [4]
or stromal cells [2,3].
Gammaretroviruses comprise a group within the larger
retrovirus family that reverse-transcribe viral RNA to a
cDNA during replication that is inserted into the host
cell chromosome. As the name indicates, XMRV is
highly related to murine leukemia virus (MLV) sharingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Rezaei et al. Virology Journal 2013, 10:20 Page 2 of 9
http://www.virologyj.com/content/10/1/2096% sequence identity [2]. In addition to PC, XMRV was
also associated with chronic fatigue syndrome (CFS) [6],
which was remarkable since no other gammaretroviruses
have been described that infect humans. However,
XMRV related xenotropic-MLV (X-MLV) are known to
infect other species including mice, koalas, cats and
non-human primates and cause leukemias, lymphomas,
neurological diseases and immunodeficiencies in these
species suggesting a plausible role for XMRV in PC [4].
In addition to the original report by Urisman and col-
leagues (2006) several other groups demonstrated an as-
sociation of XMRV with PC using nucleic acid detection
and immune based assays [3-5]. However, many other
studies either failed or were only able to detect XMRV
in a minority of PC tissue samples [7-19]. While the rea-
son for the reported disparity of XMRV prevalence in
PC was unclear, it was initially attributed to differences
in geography or assay sensitivity. However, subsequent
studies demonstrated that positive signals in sensitive
PCR assays could be ascribed to either mouse DNA con-
tamination or contamination with XMRV DNA from a
commonly used PC cell line (22Rv1), which harbours
10–20 copies of XMRV [20-26]. The discovery that
XMRV was generated by recombination of two mouse
endogenous retroviruses following passage of a PC xeno-
graft in nude mouse demonstrated that XMRV was gen-
erated in the laboratory [27].
Due to public health consequences of potential infec-
tion with XMRV or MLVs in humans, we considered it
is important to refute or confirm their association with PC
in an Australian context. This study describes the first
evaluation in Australian PC patients for the presence of
XMRV and related gammaretroviruses in matched nor-
mal and PC tissue and the elucidation of the RNASEL
genotype in Australian PC patients. In addition, patient
samples were tested for the presence of mouse DNA con-
tamination using a sensitive quantitative PCR (qPCR) assay
that detects mouse intracisternal A-type particle (IAP)
sequences. We failed to detect XMRV or related MLVs in
Australian PC patients confirming that these gammaretro-
viruses are highly unlikely to be involved in PC.
Results
Patient characteristics and RNase L genotype
The patient population comprised individuals with
higher-grade PC as determined by Gleason scores
(median 7, range 7 – 10). Consistent with PC predomin-
ately presenting in older men, the median age of patients
was 64 (range 49 – 78). The RNase L genotype was
determined using purified DNA recovered from 70
formalin-fixed paraffin-embedded (FFPE) normal and
cancer tissue from each of 35 patients. The RNase L
genotype of both samples from each patient was 100%
concordant and 8% of the patients were homozygous(QQ), 60% were heterozygous (RQ) and 32% were wild-
type (RR).
Human VAMP2 qPCR confirms integrity of DNA purified
from FFPE samples
DNA derived from FFPE samples is expected to be frag-
mented due to the fixation process and may contain
substances that are inhibitory for PCR amplification.
Therefore, to evaluate the suitability of genomic DNA
(gDNA) derived from FFPE tissue for qPCR, we deter-
mined whether we could amplify a region of the single
copy human vesicle-associated membrane protein 2
(HuVAMP2) gene. The size of the amplimer (78 bp) was
designed to be similar to the expected amplimer sizes
for qPCR detection of XMRV and MLV-related viruses
(Table 1). The linear range and sensitivity of human
VAMP2 qPCR was 1 to 107 copies per reaction (Figure 2A).
All samples tested gave HuVAMP2 values within the ac-
ceptable range and were thus deemed suitable for further
qPCR analysis. Mean HuVAMP2 copy numbers from
gDNA purified from normal and cancer tissue were similar
(P = 0.7, n = 33, Mann–Whitney U Test).
XMRV or related MLV sequences were not detected in
gDNA from paired normal and cancer tissue
To detect XMRV and related MLV sequences in a single
qPCR reaction we used broad MLV (BMLV) primers tar-
geting the conserved reverse transcriptase regions of
XMRV and Moloney murine leukemia virus (MoMLV)
(Figure 1). The linear range and sensitivity of the BMLV
primers/probe used for amplification of XMRV and
MoMLV was determined to be 1 to 107 and 1 to 106
copies per reaction, respectively (Figures 2B and 2C).
We also evaluated the linear detection range and sensi-
tivity of XMRV specific primers targeting the integrase
region of XMRV (Figure 1) [28] and determined it to be
from 1 to 107 copies of XMRV per reaction (Figure 2D).
Taken together these data demonstrate that the qPCR
assays reproducibly detected as little as 1 copy of XMRV
and MoMLV in a total of 1 μg of carrier nucleic acid.
We performed qPCR using BMLV primers on gDNA
purified from 33 normal prostate and 33 PC FFPE tissue.
DNA was subjected to three independent assays except
for 10/33 cancer and 16/33 normal tissues where only
one qPCR assay was performed due to limited amounts
of gDNA. All patient samples were negative using the
BMLV primers (Table 2). We also subjected DNA puri-
fied from 19 normal and 27 cancer samples to qPCR
using the XMRV specific primers and again found that
all samples were negative (Table 2). For both the BMLV
and XMRV specific qPCR assays, no amplification was
observed in any of the 12 negative control wells while all
positive control wells (containing 22Rv1 DNA) were
consistently positive. These data demonstrate that XMRV
Table 1 PCR primers and probes
Target Amplicon Size Method Primers and TaqMan Probe (5’-3’)
HuVAMP21 78 bp qPCR HuVAMP2-F CAGCATCTCTCCTACCCTTTCAC
HuVAMP2-R CCCCACACTTCTGGTTTTCTG
Huvamp2-Probe 6FAM-AGCAGGGATATCTAAGC-MGBNFQ2
BMLV3 76 bp qPCR BMLV-F GCCTGTCCAGGATCTGAGAG
BMLV-R GAGGTTGTAAGGGTTGGGCA
BMLV- Probe 5FAM-AAGTCAACAAGCGGGTGGAAGABHQ4
XMRVIN5 70 bp qPCR XMRVIN-F CGAGAGGCAGCCATGAAGG
XMRVIN-R GCGTATACGGGGTTGAGTCC
XMRVIN-Probe 6FAM-AGTTCTAGAAACCTCTACACTC-MGB
IAP6 71 bp qPCR MIAP-F GCCGCGCCCACATT
MIAP-R CGCAGATTATTTGTTTACCACTTAGAA
MIAP-Probe 6FAM-CCGTTACAAGATGGTGCTGA-MGBNFQ
RNASEL 137 bp PCR 462R-F GTGGAAAATGAGGAAGATGAATTTGCCAG
462Q-F GTGGAAAATGAGGAAGATGAATTTGCCAA
462-R ATTGGGGACTCACCTATTAAGATGTTTTG
1Human vesicle associated membrane protein 2.
2Minor group binding (MGB) non-fluorescent quencher.
3Primers can detect both XMRV and MLV sequences.
4Black hole quencher.
5Primers/probe specifically detect conserved integrase sequences.
6Mouse intracisternal-A particl.
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in this study.
Evidence of mouse DNA contamination in PC samples
To determine whether patient samples were contami-
nated with mouse DNA we performed qPCR with pri-
mers that detect the mouse IAP retrotransposon [28,29].
The mouse genome contains approximately 1000 IAP
copies [30], thus detection of IAPs is a highly sensitive
method for assessing mouse DNA contamination. Evalu-
ation of the linear range and sensitivity of the qPCR IAP
assay using purified Balb/c mouse gDNA showed that
the assay was highly sensitive, detecting 2 fg to 20 ng of
mouse gDNA (Figure 2E). The BMLV qPCR assay
detected from 20 fg to 20 ng of endogenous MLV
present in Balb/c gDNA (Figure 2F) indicating that this
assay was 10-fold less sensitive in detecting Balb/c
gDNA than the qPCR IAP assay.
We assessed mouse DNA contamination in gDNA
from FFPE patient samples in qPCR IAP assays and
found that 5/33 and 10/33 of normal and cancer tissues,
respectively were positive for mouse IAP (Table 2). The
level of mouse DNA contamination varied from 2 – 20 fgFigure 1 Genomic organization of XMRV and MLV showing the targe
and the XMRV specific forward (XMRVIN-F) and reverse (XMRVIN-R) p(data not shown). These data show that 23% (15/66) of
patient samples were positive for low-level mouse DNA
contamination.
Discussion
Using highly sensitive qPCR neither XMRV nor related
MLV were detected in any of the prostate tissue samples
in our Australian cohort. The BMLV qPCR assay used in
this study reproducibly detected as little as one copy of
XMRV or MoMLV DNA in a total of one μg of carrier
nucleic acid. While several studies have reportedly used
primers that simultaneously detect XMRV and related
MLV in PC samples [10,12,13,18,31], only one of these
studies reported a similar sensitivity of XMRV detection
[18] compared to this study. Also, in contrast to our
study, validation of the sensitivity of primers for detect-
ing other MLV such as MoMLV was not reported. The
reverse transcriptase target of the BMLV qPCR assay is
highly conserved demonstrating 97-100% sequence iden-
tity with preXMRV-1, preXMRV-2, Friend MLV, Friend
spleen focus-forming virus and Rauscher MLV indicat-
ing that our assay could potentially detect other MLV
gammaretroviruses apart from XMRV and MoMLV.ts of broad MLV forward (BMLV-F) and reverse (BMLV-R) primers
rimers.
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Figure 2 Linear regression analysis demonstrating the linear range and sensitivity of qPCR assays used to detect human VAMP2 in
pHuVAMP2 using HuVAMP2 primer/probes (A), XMRV in VP62 using BMLV primers/probe (B), MoMLV in pNCS using BMLV primers/
probe (C), XMRV in VP62 using XMRV-IN specific primers/probe (D), Balb/c DNA using IAP primers/probe (E) and Balb/c DNA using the
BMLV primers/probe (F). Plasmid targets at the indicated copy numbers or Balb/c DNA at the amounts shown were subjected to qPCR in the
presence of 1 μg of tRNA as the carrier nucleic acid and the logarithm of these values were plotted against the threshold cycle (CT) value. All
data points were derived from triplicate wells and the error bars denote the standard deviation. Data shown are representative of three
independent assays except for detection of XMRV in VP62 with XMRVIN specific primers (D) and Balb/c DNA detection with the BMLV primers/
probe (F), which were performed once. R2 denotes the Pearson correlation coefficient.
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samples in this study is consistent with previous findings
negating a role for these viruses in PC.
We obtained paired normal and cancer tissue from the
same patient to determine whether there was a differ-
ence in prevalence of XMRV or related MLV in these
tissues to provide clues to their role in PC pathogenesis.
This is in contrast to previous studies that have used 10μm patient tissue slices that are likely to be a mixture of
both cancer and normal tissue [4]. Our strategy also
enabled us to maximise the amount of cancer tissue
recovered to increase the probability of detecting XMRV
or related MLV in samples. We were able to selectively
obtain cancer and normal tissue by using histological
staining of tissue slices to identify appropriate regions in
the FFPE prostate tissue for obtaining the punch
Table 2 Amplification of XMRV, MLV sequences and
mouse IAPs in cancer and normal prostate tissue by qPCR
Target
Patient Tissue BMLV1 XMRV Mouse IAP
Normal 0/332 0/193 5/332
Cancer 0/332 0/273 10/332
1Detection of both XMRV and MLV sequences.
2qPCR performed in 3 independent assays, except for 10/33 cancer and 16/33
normal prostate tissue, where qPCR was performed once.
3qPCR performed once.
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DNA from FFPE tissue core biopsies suitable for down-
stream qPCR analysis that may be valuable for other
studies requiring recovery of DNA for nucleic acid
detection.
Previous studies have raised serious doubts regarding
the role of XMRV in PC and CFS. The first studies to
cast doubt on this association demonstrated that PCR
reagents and nucleic acid purification columns were
contaminated with mouse DNA that harbours MLVs
detected by highly sensitive PCR [20-24]. In addition,
the specificity of putative XMRV-specific primers detect-
ing a 24-nucleotide gag-leader deletion was challenged
with the finding that these primers were able to amplify
endogenous MLV sequences present in the gDNA of 12
different mouse strains [25]. These studies advocated the
inclusion of sensitive counter assays to detect mouse DNA
contamination to verify XMRV positive samples [13,28].
However, the remarkable nucleotide sequence identity of
XMRV from diverse patient samples remained a conun-
drum since retroviral polymerases are error prone and
therefore XMRV detected from distinct sources would be
expected to show greater sequence diversity. This finding
pointed to yet another source of patient sample contamin-
ation. Phylogenetic analysis of XMRV sequences from
unlinked patients and a commonly used PC cell line
(22Rv1) showed that these sequences formed a monophy-
letic clade and that the cell line-derived sequences were
ancestral to the patient-derived sequences (posterior prob-
ability >0.99). These findings led to the conclusion that
XMRV contamination originated from the 22Rv1 cell
line [25,26]. Furthermore, the possibility that XMRV in
22Rv1 cells originated from a bone fide human infection
was debunked by Paprotka and colleagues who showed
that XMRV was a laboratory virus generated by a rare
recombination event between two mouse endogenous
retroviruses during passage of the CWR22 PC xenograft
in nude mice from which the 22Rv1 cell line was
derived [27].
We used a previously published IAP qPCR assay [28],
to detect mouse DNA contamination in samples, which
in our hands achieved a similar detection sensitivity of2 fg of mouse gDNA. While we did not detect XMRV
or related MLV by qPCR in any of the patient sam-
ples, 15% of normal and 30% of cancer tissues were
positive for mouse IAP, which was reproducibility
observed in 2/3 independent assays in three samples and
3/3 assays in 12 samples. The level of contamination was
low and in the range of 2 – 20 fg/μg of patient DNA,
which likely explains the failure to detect mouse DNA in
these samples using the BMLV qPCR, which has a limit
of detection of 20 fg/μg gDNA.
While mouse DNA contamination was detected in seven
cancer samples in the IAP qPCR assay, no signal was
observed in normal samples from the corresponding
patients. Due to the limited amount of gDNA we were un-
able to test normal prostate tissue from one of these seven
patients. In contrast, both normal and cancer samples from
three patients were positive for mouse DNA contamination.
The greater number of mouse DNA positive samples in
cancer compared to normal tissue is unlikely due to
increased processing of the former samples because the
samples were all handled a similar number of times. In
addition, it is unlikely that PCR reagents used in this study
were contaminated with mouse DNA as none of the no
template controls (12 wells per plate) or DU145 and
LNCaP gDNA negative controls (3 wells of each per plate)
were positive for XMRV or related MLV in our qPCR
assays. Furthermore, we avoided using a Taq polymerase
that relies on a monoclonal antibody to achieve a “hot start”
as this has previously been implicated as a source of mouse
DNA contamination [22,23]. The DU145 and LNCaP
gDNA controls were also included to determine whether
there was mouse DNA contamination from DNA extrac-
tion columns [24]. While we did not observe any positive
signals in these controls, the sporadic nature of this con-
tamination makes it difficult to exclude this possibility. In
addition, procedures were implemented to prevent cross
contamination of samples during tissue biopsy collection at
TissuPath; however, the presence of mouse DNA during
the original processing of the samples cannot be excluded.
Therefore, the contamination observed is likely to be ran-
dom and possibly due to the DNA extraction columns and/
or contamination during the original fixation and paraffin
embedding of the prostate tissue, microtome sectioning of
samples or preparation of the punch biopsies for this study.
One potential limitation of our study is that we used
naked plasmid DNA for determining the analytical
range of the qPCR assays used in this study while the
samples were formalin-fixed DNA from tissue. This
may have led to possible overestimation of the sensitiv-
ity of the assays. Regardless, our findings are consistent
with previous studies demonstrating no association be-
tween XMRV and related gammaretroviruses in prostate
cancer patients undertaken in regions geographically
distinct from Australia.
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genotype of patients in our cohort was to establish if
there was an association with the homozygous (QQ)
RNase L variant and XMRV or related MLVs. The RNase
L enzyme is an interferon-induced ribonuclease, which
has antiviral activity and can also induce apoptosis
[32,33]. Men that are heterozygous or homozygous for
the mutant form of the allele have 50% and greater than
2-fold increased risk, respectively of PC than non-
carriers [34]. Given the role of RNase L in antiviral
defense, it has been proposed that a viral infection may
contribute to PC [2]. Since none of our samples were
positive for XMRV or related MLVs, an association be-
tween RNASEL mutation and infection with these
viruses could not be investigated. Regardless, we suc-
cessfully determined the RNASEL genotype for all DNA
samples purified from FFPE cancer and normal prostate
tissue using a previously published allele specific PCR
assay [34]. The genotypes determined for cancer and
normal prostate tissue from the same patient, which
were performed blinded, were 100% concordant. To our
knowledge this is the first time that the RNASEL geno-
type of Australian PC patients has been determined. The
overall allele distribution in our small cohort appears to
be similar to non-hereditary PC cases observed in the
USA where the heterozygous (RQ) allele has the greatest
prevalence (~47%) and the homozygous (QQ) allele the
lowest prevalence (9.9 – 15.2%) [4,35]. Further studies
with a larger cohort would be of interest to determine
whether the RNASEL allele distribution in Australian PC
patients are distinct to normal men in the same geo-
graphical region, if there are racial differences, and
whether there is an association of this allele with disease
severity.
Conclusions
The Blood XMRV Scientific Working Group’s findings,
along with the discovery that XMRV is a virus generated
by a rare recombination event in the laboratory has pro-
vided irrefutable evidence that XMRV or related MLV
are not associated with CFS [27,36,37]. These reports
have lead to the retraction of the original study describ-
ing the association of XMRV with CFS [6,38]. In
addition, a separate study has confirmed that XMRV or
closely related viruses were not present in the primary
tissues from which the XMRV-infected cell line 22Rv1
was derived [31]. Furthermore, strong evidence for
XMRV infection of human cells in the prostate as
demonstrated by XMRV DNA joined to human DNA
sequences has been found to be due to DNA contamin-
ation from XMRV infected DU145 PC cells used in the
same laboratory [26,39]. The absence of XMRV and
related MLV in Australian PC patients using a highly
sensitive pPCR assay is consistent with previous reportsconcluding that XMRV and related MLV positive signals
in patient samples are due to contamination and that
there is no causal link between these gammaretroviruses
and PC.
Added in proof: Following submission of our study a
report by Lee and colleagues [40] demonstrated that
archival RNA from prostate cancer samples used in the
first study reporting an association between XMRV and
PC [2] was contaminated with XMRV originating from a
XMRV-infected cell line which led to the retraction of
the original report in PLoS Pathogens. In addition, a
multicenter-blinded analysis headed by Ian Lipkin which
analyzed peripheral blood from well-characterized and
geographically diverse populations of CFS and myalgic
encephalomyelitis (MS) patients demonstrated no asso-
ciation with either XMRV or polytropic MLV [41].Methods
Study population and specimens
Prostate samples used in this study were archival FFPE
tissue obtained from patients in the greater Melbourne
area who had radical prostatectomies performed with
tissues submitted to TissuPath Specialist Pathology
(Mount Waverley, Victoria, Australia) for diagnostic
pathology between 2007 and 2011. For this study, the
samples were prepared by TissuPath scientists from nor-
mal and cancer affected regions of the prostate, guided
by the associated haematoxylin and eosin (H&E) stained
tissue sections which had been evaluated by light micros-
copy. Samples were received as 2–3 FFPE punch biopsies
of 2 mm × 2 mm (diameter × depth). Specimens, coded to
mask whether they were normal or cancer tissue and to
maintain patient confidentiality, were provided to investi-
gators at the Burnet Institute. Samples were unblinded
following completion of the assays at which time the age
and Gleason scores for each patient was provided. The
study was approved by the Alfred Health Human Ethics
Committee (Project Number 32/11).Cell lines
The human prostate carcinoma cell line 22Rv1 [42] and the
human embryonic lung fibroblast cell line MRC-5 [43],
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Human prostate carcinoma
cell lines, DU145 [44] and LNCaP [45] were provided by
Renee Taylor and Gail Risbridger (Monash University,
Clayton, Australia). Human peripheral blood mononuclear
cells (PBMCs) were isolated from donor buffy coat packs
(from donors screened for the absence of blood pathogens)
obtained from the Australian Red Cross (Melbourne,
Australia) and purified by Ficoll-Paque™ PLUS centrifuga-
tion according to manufacturer’s instructions (GE Healthcare,
Uppsala, Sweden).
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The plasmid, pVP62, encodes the full length molecular
clone of XMRV inserted in the mammalian expression vec-
tor pcDNA3.1(−) and was obtained from the NIH AIDS
Research & Reference Reagent Program [2]. pNCS, a gift
from Stephen Goff (Columbia University, New York, USA)
encodes the full length molecular clone of MoMLV and is a
derivative of pNCA carrying an SV40 origin of replication
in the plasmid backbone [46]. pHuVAMP2, harbouring the
human vesicle-associated membrane protein 2 (VAMP2)
gene, was generated by PCR amplification from gDNA puri-
fied from DU145 cells using HuVAMP2-F and HuVAMP2-
R primers (Table 1). The 78 bp amplicon was cloned into
the TOPO TA vector according to manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA, USA) and the identity of
the clone verified by nucleotide sequencing.
Laboratory techniques to prevent sample contamination
To avoid cross contamination each tissue sample was
obtained using a separate sterile 2 mm punch biopsy. To
minimize the exposure of patient samples to potential
sources of mouse, XMRV and MLV DNA, standard labora-
tory procedures for sterile DNA extraction were practiced
when handling and processing specimens for purification of
gDNA and PCR. These measures included the use of sterile
UV irradiated microcentrifuge tubes, filter-barrier pipette
tips and dedicated micropipettes. All tissue processing was
performed in a biosafety class II cabinet and equipment
was exposed to UV light for 15–20 min prior to use.
Genomic DNA purification from FFPE prostate tissue and
cell lines
gDNA was purified from FFPE patient tissue using the
QIAampW DNA FFPE Tissue Kit and the QIAGEN Depar-
afinisation solution (DPS, QIAGEN, Hilden, Germany).
Since the QIAamp kit recommends extracting gDNA from
tissue sections of 10 μm in thickness, we introduced modi-
fications to optimise DNA recovery from the thicker core
biopsies used in this study. These modifications included
trimming excess paraffin from the core biopsies, dissecting
the tissues into a maximum of five pieces prior to the
addition of DPS, and an overnight incubation of tissues
with proteinase K. gDNA was extracted from a total of 70
prostate tissue punch biopsies. gDNA was purified from
DU145, LNCaP, MRC-5, 22Rv1 cells and PBMCs using
the DNeasy Blood and Tissue Kit (QIAGEN) according to
manufacturer’s instructions.
Amplification refractory mutation system (ARMS) to
detect RNase L R462Q polymorphisms
The RNase L R462Q polymorphism in patient samples was
determined using the ARMS assay as previously published
[34]. ARMS is an allele specific PCR assay that uses two
forward primers with different 3’-termini to specificallydetect either the wild-type R462 (462R-F) or the mutant
R462Q (462Q-F) allele, while the reverse primer (462-R)
detects both alleles (Table 1). Each assay included control
DNA from DU145, LNCaP and 22Rv1 PC cell lines that
have the RQ, RR and QQ RNase L genotypes, respectively
and 20 ng of gDNA from FFPE samples, and was per-
formed in three independent assays.
Human vesicle-associated membrane protein 2
(HuVAMP2) qPCR
To verify the quality of gDNA purified from FFPE tissue
and to rule out the presence of PCR inhibitors, patient
samples were subjected to a qPCR assay targeting the
human VAMP2 gene as described previously [28]. Quanti-
tative standards of pHuVAMP2 was prepared as 10-fold
serial dilutions from 107 to 100 copies in the presence of 1
μg Saccharomyces cerevisiae transfer RNA (tRNA) carrier
nucleic acid per reaction (Sigma-Aldrich). PCR was per-
formed using 10 μl of diluted pHuVAMP2 containing the
required plasmid copy numbers or 1 μg of sample gDNA
in a final volume of 25 μl. Threshold cycle (Ct) values that
were not within the average Ct ± SD (8.9×105 ± 5.4×105
copies/μg) for gDNA from 22Rv1, LNCaP, DU145 and
human PBMCs were considered unsuitable for further
analysis by qPCR.
qPCR detection of XMRV and MLV using broad MLV
(BMLV) and XMRV specific primers/probe
To detect XMRV and related MLV sequences we used
primers (BMLV-F and BMLV-R) and the TaqMan probe
(BMLV-Probe) targeting conserved regions in the reverse
transcriptase region of XMRV and MoMLV pol (Figure 1)
(Table 1) [47]. These BMLV primers/probe also have 97-
100% nucleotide sequence homology to Friend MLV,
Rauscher MLV, Friend spleen focus forming virus,
preXMRV-1 and preXMRV-2. In addition, we also used
the XMRV specific primers (XMRVIN-F, XMRVIN-R)
and probe (XMRVIN-Probe) (Table 1), which target the
integrase region of XMRV (Figure 1) as published previ-
ously [28]. Quantitative standards of XMRV (pVP62)
and MoMLV (pNCS) were prepared by subjecting plas-
mids to serial dilutions from 107 to 100 copies and 106
to 100 copies, respectively. PCR was performed as pub-
lished [47] using the required copies of plasmid DNA
(in the presence of 1 μg of carrier tRNA) or 1 μg of sam-
ple gDNA in a final volume of 25 μl.
qPCR detection of mouse IAP
qPCR for mouse IAP sequences was used as a marker of
mouse DNA contamination as previously described (Table 1)
[28]. Serial dilutions (2 fg to 200 ng) of Balb/c gDNA
(Sigma) were used as quantitative standards. PCR reac-
tions included the required amounts of standard Balb/c
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sample gDNA in a final volume of 25 μl.
Interpretation of qPCR signals detected in patient samples
For detection of XMRV/MLV or mouse DNA contamin-
ation, signals that were greater than two standard devia-
tions (SD) from the average Ct of the lowest standard
tested (i.e., 1 copy of plasmid or 2 fg of mouse DNA) were
considered negative. Samples where a signal was detected
within the linear range of the assay and in the majority of
independent assays performed, were considered positive.
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